Literature DB >> 12771024

Engineering cancer resistance in mice.

Peter Klatt1, Manuel Serrano.   

Abstract

Research on cancer has benefited enormously from the genetic manipulation of mice. Until recently, most of the emphasis has been put on tailoring genetic alterations to accelerate tumorigenesis or to recapitulate particular aspects of the tumorigenic process. The goal of engineering mice with an increased resistance to cancer is a novel aspect that is of importance to understand cancer susceptibility and to validate therapeutic and chemopreventive strategies. Here, we review the different mouse models described to date that manifest a 'cancer resistance' phenotype, with a particular emphasis on the molecular basis of the resistance and on the associated phenotypes that may have a negative impact on health.

Entities:  

Mesh:

Year:  2003        PMID: 12771024     DOI: 10.1093/carcin/bgg057

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  4 in total

Review 1.  Using mice to examine p53 functions in cancer, aging, and longevity.

Authors:  Lawrence A Donehower
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-11-04       Impact factor: 10.005

2.  Conditional ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for cell survival and mouse skin tumorigenesis.

Authors:  E Sterneck; S Zhu; A Ramirez; J L Jorcano; R C Smart
Journal:  Oncogene       Date:  2006-02-23       Impact factor: 9.867

3.  Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity.

Authors:  Lynette Moore; Xiongbin Lu; Nader Ghebranious; Stuart Tyner; Lawrence A Donehower
Journal:  Mech Ageing Dev       Date:  2007-11-01       Impact factor: 5.432

Review 4.  Genetically modified mouse models in cancer studies.

Authors:  Javier Santos; Pablo Fernández-Navarro; María Villa-Morales; Laura González-Sánchez; José Fernández-Piqueras
Journal:  Clin Transl Oncol       Date:  2008-12       Impact factor: 3.405

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.